Larimar Therapeutics (LRMR) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Lyell Immunopharma (LYEL) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 50.8% versus a loss of 52.7%. Over five years, LRMR leads with a -84.5% price change compared with -97.1% for LYEL. Larimar Therapeutics is the larger company by market cap ($206.2 million vs $199.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | LYEL |
|---|---|---|
| Share price | $1.99 | $8.12 |
| Market cap | $206.21M | $198.98M |
| 1-day change | -0.25% | -0.85% |
| YTD return | -47.90% | -73.62% |
| 1-year return | -52.74% | -50.79% |
| 5-year return | -84.48% | -97.06% |
| EPS (TTM) | $-1.99 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $36.00K |
| Revenue growth (YoY) | — | -40.98% |
| Net income (latest FY) | $-165.67M | $-274.45M |
| Operating margin | — | -748344.44% |
| Net margin | — | -762355.56% |
| 52-week high | $6.42 | $45.00 |
| 52-week low | $1.92 | $7.20 |
| Distance from 52-week high | -69.08% | -81.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +625.44% | +366.50% |
| Average volume | 1.31M | 152.61K |
| Shares outstanding | 103.88M | 24.51M |
| Employees | 71 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
LRMR vs LYEL FAQ
Which is bigger, Larimar Therapeutics or Lyell Immunopharma?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $206.21M compared with $198.98M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, LRMR or LYEL?
LYEL returned -50.79% over the past 12 months, compared with -52.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.